Drugs / FGF-2
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04361630 | May → Nov 2019 | periodontitis | SVS Institute of Dental Sciences | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04960384 | May 2022 → Sep 2025 | tympanic membrane disorder | NYU Langone Health | Completed | No outcome recorded |
| Phase 2 | NCT02307916 | Oct 2016 → Jul 2019 | tympanic membrane disorder | D. Bradley Welling, MD, PhD | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2007-09-28 | Kaken Pharmaceutical | Results 歯周組織再生治療剤「KCB-1D」の後期第Ⅱ相試験結果について eir-parts.net ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2007-09-28 | Kaken Pharmaceutical | 歯周組織再生治療剤「KCB-1D」の後期第Ⅱ相試験結果について eir-parts.net ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FGF 2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04361630 ↗ |
| Known as | human fibroblast growth factor-2 | “human fibroblast growth factor-2 (FGF-2)” NCT04960384 ↗ |
| Modality | Protein / enzyme biologic | “human fibroblast growth factor-2 (FGF-2)” NCT02307916 ↗ |
| Route | Topical | “topical application” NCT02307916 ↗ |